Background: Primary aldosteronism is a leading cause of secondary hypertension and is associated with increased cardiovascular risk. Accurate localization of aldosterone-producing lesions is essential to guide curative treatment. Although adrenal venous sampling (AVS) remains the gold standard for subtyping, it is invasive and not widely available. Recent advances in molecular imaging, including 68Ga-Pentixafor PET/CT targeting CXCR4, have shown potential for non-invasive localization of functional adrenal lesions.
Purpose: To assess the pooled diagnostic accuracy of 68Ga-Pentixafor PET/CT for detecting aldosterone-producing lesions.
Methods: A systematic review and meta-analysis were conducted following PRISMA-DTA guidelines. Databases including PubMed, Embase, Scopus, Web of Science, and CENTRAL were searched through January 2025. Eligible studies included adult patients with primary aldosteronism who underwent 68Ga-Pentixafor PET/CT, with reference standards including AVS, histopathology, or immunohistochemistry. Diagnostic accuracy outcomes were pooled using a bivariate random-effects model.
Results: Eight studies comprising 564 patients were included. Agreement between reviewers during full-text assessment was almost perfect (Cohen's κ = 0.93). Pooled sensitivity was 83% (95% CI: 75-89), specificity 94% (95% CI: 83-98), AUC 0.91 (95% CI: 0.88-0.93), LR+ 14.6 (95% CI: 5.3-40.2), and LR- 0.18 (95% CI: 0.12-0.27). Diagnostic performance remained stable across subgroups, with no significant variation according to tracer dose, SUVmax, acquisition time, study design, or CXCR4/CYP11B2 expression. No evidence of publication bias was detected (Deeks' test, p = 0.93).
Conclusions: 68Ga-Pentixafor PET/CT demonstrates high diagnostic accuracy for identifying aldosterone-producing lesions and may serve as a reliable, non-invasive alternative to AVS in selected patients.
Purpose: To determine whether wash-in (WI) and wash-out (WO) rates of contrast involving the future liver remnant (FLR) based on 2-dimensional venograms following portal vein embolization (PVE) can predict liver hypertrophy.
Methods: This is a single-center, retrospective, observational, cohort study of consecutive patients who underwent PVE from August 2019 to March 2024 during which the post-PVE venogram was obtained for more than 15 s. Enhancement of the FLR on post-PVE venograms was plotted as a function of time. Piecewise linear fits were applied to the datasets to derive WI and WO rates. Rates were compared to degree of hypertrophy (DH) and kinetic growth rate (KGR).
Results: 16 patients who underwent PVE were included in the analysis (RPVE, n = 10; RPVE+4, n = 6). Median standardized FLR (sFLR) prior to PVE increased from 23% (median, range 15-49%) to 34% (median, range 24-54%), P = 0.0008. DH was 11.9% (median, range 2.0-19.9%) and KGR was 2.5% (median, range 0.5-4.7%). WI rates measured 0.0878 (median, range 0.0669-0.1760). WO rates measured 0.0315 (median, range 0.0039-0.0473). WO:WI ratios measured 0.2886 (median, range 0.0538-0.5760). Spearman's rank order correlations were calculated between WO:WI and DH (ρ = 0.6265) as well as WO:WI and KGR (ρ = 0.6529). Multivariate linear regression analysis of WO:WI with DH and KGR yielded P-values of 0.0470 and 0.0980, respectively.
Conclusions: WO:WI ratios of the FLR calculated from 2-dimensional venograms following PVE may correlate with DH, providing immediate post-PVE assessment of the regenerative capacity of the FLR.

